COMPANY

Collaborations Pharmaceuticals

Keywords: protein therapeutics neuronal ceroid lipofuscinosis 1 opioid use disorder

Location: Raleigh, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $307K (SBIR Phase I 1R43AI191982-01A1, new, notice Aug 27, 2026). NIH RePORTER 1R43AI191982-01A1 (Aug 27, 2026)
Evidence (1 event)
- Aug 27, 2026 · NIH RePORTER 1R43AI191982-01A1
  Organization: COLLABORATIONS PHARMACEUTICALS, INC.; City/State: FUQUAY VARINA, NC; Project number: 1R43AI191982-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 306870; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Long-term formulation for combination antiviral treatment of HIV; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 1, 2026 Grant Government grant announced Sep 1, 2026. Source: company's own press page. source ↗
Oct 7, 2025 Partnership Partnership / licensing announced Oct 7, 2025. Source: company's own press page. source ↗

Last 2 years.

Oct 7, 2025 Partnership / licensing announced Oct 7, 2025. Source: company's own press page. source ↗
Sep 1, 2026 Government grant announced Sep 1, 2026. Source: company's own press page. source ↗